Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 913.87M |
| Revenue (ttm) | 185.74M |
| Net Income (ttm) | -130.77M |
| Shares Out | 257.07M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 950,536 |
| Open | 3.640 |
| Previous Close | 3.680 |
| Day's Range | 3.515 - 3.705 |
| 52-Week Range | 1.950 - 4.105 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 4.13 (+16.17%) |
| Earnings Date | May 7, 2026 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents ... [Read more]
Financial Performance
In 2025, MRVI's revenue was $185.74 million, a decrease of -28.34% compared to the previous year's $259.19 million. Losses were -$130.77 million, -9.72% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price target is $4.13, which is an increase of 16.17% from the latest price.
News
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fi...
Maravai LifeSciences Holdings Earnings Call Transcript: Q4 2025
Delivered revenue and adjusted EBITDA above expectations, driven by cost savings, new product launches, and strong customer demand. Guidance for 2026 calls for 8–13% revenue growth, margin expansion, and continued operational improvements.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fo...
Maravai LifeSciences Holdings Transcript: Jefferies London Healthcare Conference 2025
Management executed major cost reductions and centralized operations, setting up for scalable growth and profitability. Focused on high-impact products and larger customer orders, the business expects improved visibility, new product traction, and international expansion to drive growth through 2026.
Maravai LifeSciences Holdings Transcript: Stifel 2025 Healthcare Conference
Leadership executed a major restructuring, improving forecasting and focusing sales on higher-value opportunities. Financial performance is on track, with strong Q4 growth expected and COVID revenues set to return. mRNA innovation and a diversified customer base position the company for steady growth.
Maravai LifeSciences Announces November 2025 Investor Conference Schedule
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the...
Maravai LifeSciences Holdings Earnings Call Transcript: Q3 2025
Q3 revenue declined year-over-year due to order timing and COVID product headwinds, but cost restructuring and innovation initiatives are positioning for strong Q4 growth and a return to positive adjusted EBITDA in 2026. BST showed solid growth, while NAP is expected to rebound next quarter.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders
Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its th...
Maravai LifeSciences Holdings Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue decline and a larger net loss, but base business grew modestly. Major restructuring aims to cut $50M+ in annual costs, with a focus on operational efficiency and digital expansion. Positive adjusted EBITDA and free cash flow are targeted for H2 2026, independent of high-volume CleanCap.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans t...
Johnson Fistel, PLLP Investigates Quantum Computing, AppLovin, Skyworks Solutions, and Maravai LifeSciences
SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating potential violations of federal and state securities laws by certain officers and directo...
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today an...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or ...
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "...